1. Phylogeny  
STK33 is a serine/threonine kinase that is a member of the eukaryotic kinome and is classified within the calcium/calmodulin‐dependent kinase (CAMK) group, although it notably lacks a canonical calcium/calmodulin binding domain. Sequence comparisons indicate that the catalytic domain of STK33 shares only approximately 28% identity with that of the STK35L1 kinase, placing it in a distinct evolutionary branch separate from the STK35 family. Some studies report that STK33 orthologs can be traced back as far as the early metazoans; for example, its presence in the sea anemone genome suggests an origin approximately 700 million years ago, predating the emergence of vertebrate-specific STK35 homologs that arose around 550 million years ago (goyal2009identifyingandcharacterizing pages 11-13). In contrast, research focused on its function in spermatogenesis in mammalian systems has emphasized that STK33 is highly conserved among mammals, with sequence identity reaching 97–98% among human, mouse, rat, dog, and cow proteins (spiridonov2005identificationandcharacterization pages 2-4). This apparent discrepancy highlights a contradiction in the literature regarding the evolutionary history of STK33: while some sources extend its phylogenetic distribution to early metazoans, others restrict its conservation predominantly to the mammalian lineage (goyal2009identifyingandcharacterizing pages 11-13, spiridonov2005identificationandcharacterization pages 2-4). Overall, the current consensus situates STK33 as a CAMK family serine/threonine kinase that, despite its modest sequence similarity to kinases in the STK35 subfamily, has evolved along a distinct trajectory marked by specialized functions in reproductive biology (bradley2019evolutionofprotein pages 2-3).

2. Reaction Catalyzed  
STK33 catalyzes the transfer of a phosphate group from adenosine triphosphate (ATP) to hydroxyl groups on serine or threonine residues of substrate proteins. This biochemical reaction can be summarized as follows:  
  ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺  
This reaction, which is common to serine/threonine kinases, underlies its role in modifying substrates through phosphorylation, thereby altering their function, interaction potential, and stability (luo2012stk33kinaseinhibitor pages 1-2).

3. Cofactor Requirements  
The catalytic activity of STK33 is dependent on the presence of divalent metal ions, with Mg²⁺ being the primary cofactor required for efficient ATP binding and phosphotransfer. In vitro kinase assays typically include MgCl₂ in the reaction buffer to facilitate these enzymatic processes (luo2012stk33kinaseinhibitor pages 5-6).

4. Substrate Specificity  
STK33 exhibits a relatively narrow substrate specificity profile compared to other serine/threonine kinases. Biochemical studies have demonstrated that STK33 is capable of autophosphorylation, with multiple autophosphorylation sites having been identified at residues such as Thr440, Ser441, Thr491, Ser493, and Thr496 (luo2012stk33kinaseinhibitor pages 2-2). In addition, in vitro experiments have shown that STK33 can phosphorylate generic substrates such as myelin basic protein (MBP). Its substrate repertoire is limited, with reports indicating that STK33 phosphorylates only a small number of proteins when compared to other kinases such as STK17A, which has been characterized as having a broader substrate range (bradley2019evolutionofprotein pages 12-14, sugiyama2019largescalediscoveryof pages 3-4). By similarity, STK33 is proposed to phosphorylate key cytoskeletal proteins; its documented activity against vimentin suggests a role in regulating intermediate filament dynamics, while bioinformatic similarity supports the possibility that it also phosphorylates fibrous sheath proteins AKAP3 and AKAP4. These substrates are implicated in sperm flagella assembly during spermatogenesis, further underlining its specialized role in reproductive biology (spiridonov2005identificationandcharacterization pages 7-9).

5. Structure  
Although an experimentally determined crystal structure of STK33 is not available within the provided literature, sequence analysis and predictive modeling indicate that STK33 exhibits a canonical eukaryotic protein kinase fold. The protein is composed of approximately 514 amino acids with an overall molecular weight near 57.8 kDa. Its structure is predicted to have the typical bilobal architecture seen in serine/threonine kinases, with a smaller N-terminal lobe responsible for ATP binding and characterized by a glycine-rich loop, and a larger C-terminal lobe housing the catalytic loop and activation segment. This activation segment contains key conserved motifs such as the DFG (Asp-Phe-Gly) motif and the HRD (His-Arg-Asp) motif present in the catalytic loop, which are critical for coordinating substrate binding and catalysis (luo2012stk33kinaseinhibitor pages 1-2, spiridonov2005identificationandcharacterization pages 1-2). Notably, STK33 does not possess the calcium/calmodulin binding domain that is typical of many members of the CAMK family, a feature that distinguishes its structure and regulatory mechanisms from classical calcium-dependent kinases. In addition, the predicted three-dimensional model—derived from computational tools such as AlphaFold—suggests that the overall structural organization of STK33 is consistent with other serine/threonine kinases, featuring a well-defined active site and conserved structural elements required for its enzymatic function (spiridonov2005identificationandcharacterization pages 1-2).

6. Regulation  
The regulatory mechanisms controlling STK33 activity are primarily post-translational in nature. Autophosphorylation plays a critical role in modulating the kinase’s activity; multiple autophosphorylation sites have been identified (including Thr440, Ser441, Thr491, Ser493, and Thr496), and these modifications are thought to be essential for achieving full catalytic activity (luo2012stk33kinaseinhibitor pages 2-2, luo2012stk33kinaseinhibitor pages 6-6). Furthermore, studies have demonstrated that STK33 forms stable complexes with molecular chaperones such as HSP90-1, HSC70, and HSP70-1. These chaperone interactions are required for proper folding and stabilization of the kinase, thereby indirectly affecting its activity (spiridonov2005identificationandcharacterization pages 4-5). While no external regulatory domains—such as classical inhibitory domains or Ca²⁺/calmodulin binding motifs—have been described for STK33, its activity is inherently regulated by its autophosphorylation status and association with molecular chaperones, which together ensure appropriate kinase function in the cellular context.

7. Function  
STK33 plays an essential role in reproductive biology, particularly in spermatid differentiation and male fertility. Functional studies in mammalian models have demonstrated that the kinase is required for proper spermatogenesis; deletion or mutation of STK33 leads to defects in sperm morphology, impaired sperm flagella assembly, and subsequent male infertility (spiridonov2005identificationandcharacterization pages 7-9, spiridonov2005identificationandcharacterization pages 9-11). At the molecular level, STK33 facilitates sperm flagella assembly by mediating the phosphorylation of fibrous sheath proteins, including AKAP3 and AKAP4, which are critical for the structural organization of the flagellar apparatus. Additionally, STK33 phosphorylates vimentin, thereby modulating the dynamics of the intermediate filament cytoskeleton. These phosphorylation events are believed to be crucial for the proper remodeling of the cytoskeleton during the complex process of spermatid differentiation. Beyond its established role in spermatogenesis, STK33 has been implicated in human cancer biology. Some studies have investigated its potential involvement in KRAS-dependent tumorigenesis, reporting that although RNA interference-mediated knockdown of STK33 can reduce the viability of certain cancer cell lines, potent small-molecule inhibitors such as BRD8899 fail to exert similar cytotoxic effects. Moreover, somatic mutations in STK33, including a heterozygous F323L mutation identified in pancreatic cancer, have been reported in mutation prioritization studies, highlighting a potential role in oncogenic signaling (luo2012stk33kinaseinhibitor pages 2-3, carter2010prioritizationofdriver pages 2-3). Nonetheless, the primary biological function of STK33 remains anchored in its critical role in male germ cell development, where its kinase activity is indispensable for ensuring proper sperm maturation and flagellar formation.

8. Other Comments  
Experimental inhibitors targeting STK33 have been developed, most notably the fasudil-derived compound BRD8899, which demonstrates potent nanomolar inhibition of STK33 autophosphorylation in biochemical assays. Despite its high biochemical potency, BRD8899 does not translate into reduced viability in KRAS-mutant cancer cell lines, thereby questioning the efficacy of STK33 kinase inhibition as an anti-cancer strategy (luo2012stk33kinaseinhibitor pages 2-3, luo2012stk33kinaseinhibitor pages 6-6). In addition to its potential involvement in cancer, STK33 mutations such as the heterozygous F323L variant have been identified through high-throughput mutation screening in pancreatic cancer, suggesting that alteration of STK33’s function may contribute to tumorigenesis in certain contexts (carter2010prioritizationofdriver pages 2-3, carter2010prioritizationofdriver pages 5-6). Nevertheless, the overwhelming functional data from studies in reproductive biology underscore that STK33 is primarily a kinase required for spermatid differentiation and the assembly of sperm flagella. This duality of function—one in normal reproductive development and a potential, albeit controversial, role in oncogenic processes—highlights the complexity of its regulatory and substrate specificity profiles. Current research efforts continue to explore the possibility of developing more selective inhibitors and to delineate the precise molecular mechanisms through which STK33 exerts its functions in both healthy and disease states.

9. References  
1. Goyal, P., Behring, A., Kumar, A., and Siess, W. “Identifying and Characterizing a Novel Protein Kinase STK35L1 and Deciphering Its Orthologs and Close-Homologs in Vertebrates.” PLoS ONE, 4:e6981, Sep 2009, pages 1-2, 6-7, 11-13.  
2. Luo, T., Masson, K., Jaffe, J. D., Silkworth, W., Ross, N. T., Scherer, C. A., Scholl, C., Fröhling, S., Carr, S. A., Stern, A. M., Schreiber, S. L., and Golub, T. R. “STK33 Kinase Inhibitor BRD-8899 Has No Effect on KRAS-Dependent Cancer Cell Viability.” Proceedings of the National Academy of Sciences, 109:2860-2865, Feb 2012, pages 1-2, 2-2, 5-6, 6-6, 2-3.  
3. Park, G., Servin, J. A., Turner, G. E., Altamirano, L., Colot, H. V., Collopy, P., Litvinkova, L., Li, L., Jones, C. A., Diala, F.-G., Dunlap, J. C., and Borkovich, K. A. “Global Analysis of Serine-Threonine Protein Kinase Genes in Neurospora crassa.” Eukaryotic Cell, 10:1553-1564, Nov 2011, pages 1-2, 3-4, 4-5.  
4. Bradley, D. and Beltrao, P. “Evolution of Protein Kinase Substrate Recognition at the Active Site.” PLOS Biology, 17:e3000341, Jun 2019, pages 2-3, 6-8, 8-9, 12-14.  
5. Janczarek, M., Vinardell, J.-M., Lipa, P., and Karaś, M. “Hanks-Type Serine/Threonine Protein Kinases and Phosphatases in Bacteria: Roles in Signaling and Adaptation to Various Environments.” International Journal of Molecular Sciences, 19:2872, Sep 2018, pages 1-3, 8-10.  
6. Spiridonov, N. A., Wong, L., Zerfas, P. M., Starost, M. F., Pack, S. D., Paweletz, C. P., and Johnson, G. R. “Identification and Characterization of SSTK, a Serine/Threonine Protein Kinase Essential for Male Fertility.” Molecular and Cellular Biology, 25:4250-4261, May 2005, pages 1-2, 2-2, 2-4, 4-5, 7-9, 9-11.  
7. Sugiyama, N., Imamura, H., and Ishihama, Y. “Large-Scale Discovery of Substrates of the Human Kinome.” Scientific Reports, Jul 2019, pages 3-4.  
8. Sun, E., Liu, C., Ma, Z., Mou, X., Mu, X., Ni, Y., Li, X. L., Zhang, D., and Ju, Y. “Knockdown of Human Serine/Threonine Kinase 33 Suppresses Human Small Cell Lung Carcinoma by Blocking RPS6/BAD Signaling Transduction.” Neoplasma, 64(6):869-879, 2017, pages 1-2, 7-10.  
9. Wang, J., Ji, X., Liu, J., and Zhang, X. “Serine/Threonine Protein Kinase STK16.” International Journal of Molecular Sciences, 20:1760, Apr 2019, pages 1-3.  
10. Zhou, B., Xiang, J., Zhan, C., Liu, J., and Yan, S. “STK33 Promotes the Growth and Progression of Human Pancreatic Neuroendocrine Tumour via Activation of the PI3K/AKT/mTOR Pathway.” Neuroendocrinology, 110:307-320, Jul 2020, pages 19-21, 27-29.  
11. Carter, H., Samayoa, J., Hruban, R. H., and Karchin, R. “Prioritization of Driver Mutations in Pancreatic Cancer Using Cancer-Specific High-Throughput Annotation of Somatic Mutations (CHASM).” Cancer Biology & Therapy, 10:582-587, Sep 2010, pages 2-3, 5-6.

References

1. (bradley2019evolutionofprotein pages 12-14): David Bradley and Pedro Beltrao. Evolution of protein kinase substrate recognition at the active site. PLOS Biology, 17:e3000341, Jun 2019. URL: https://doi.org/10.1371/journal.pbio.3000341, doi:10.1371/journal.pbio.3000341. This article has 76 citations and is from a highest quality peer-reviewed journal.

2. (goyal2009identifyingandcharacterizing pages 11-13): Pankaj Goyal, Antje Behring, Abhishek Kumar, and Wolfgang Siess. Identifying and characterizing a novel protein kinase stk35l1 and deciphering its orthologs and close-homologs in vertebrates. PLoS ONE, 4:e6981, Sep 2009. URL: https://doi.org/10.1371/journal.pone.0006981, doi:10.1371/journal.pone.0006981. This article has 15 citations and is from a peer-reviewed journal.

3. (luo2012stk33kinaseinhibitor pages 1-2): Tuoping Luo, Kristina Masson, Jacob D. Jaffe, Whitney Silkworth, Nathan T. Ross, Christina A. Scherer, Claudia Scholl, Stefan Fröhling, Steven A. Carr, Andrew M. Stern, Stuart L. Schreiber, and Todd R. Golub. Stk33 kinase inhibitor brd-8899 has no effect on kras-dependent cancer cell viability. Proceedings of the National Academy of Sciences, 109:2860-2865, Feb 2012. URL: https://doi.org/10.1073/pnas.1120589109, doi:10.1073/pnas.1120589109. This article has 99 citations.

4. (luo2012stk33kinaseinhibitor pages 2-2): Tuoping Luo, Kristina Masson, Jacob D. Jaffe, Whitney Silkworth, Nathan T. Ross, Christina A. Scherer, Claudia Scholl, Stefan Fröhling, Steven A. Carr, Andrew M. Stern, Stuart L. Schreiber, and Todd R. Golub. Stk33 kinase inhibitor brd-8899 has no effect on kras-dependent cancer cell viability. Proceedings of the National Academy of Sciences, 109:2860-2865, Feb 2012. URL: https://doi.org/10.1073/pnas.1120589109, doi:10.1073/pnas.1120589109. This article has 99 citations.

5. (luo2012stk33kinaseinhibitor pages 5-6): Tuoping Luo, Kristina Masson, Jacob D. Jaffe, Whitney Silkworth, Nathan T. Ross, Christina A. Scherer, Claudia Scholl, Stefan Fröhling, Steven A. Carr, Andrew M. Stern, Stuart L. Schreiber, and Todd R. Golub. Stk33 kinase inhibitor brd-8899 has no effect on kras-dependent cancer cell viability. Proceedings of the National Academy of Sciences, 109:2860-2865, Feb 2012. URL: https://doi.org/10.1073/pnas.1120589109, doi:10.1073/pnas.1120589109. This article has 99 citations.

6. (luo2012stk33kinaseinhibitor pages 6-6): Tuoping Luo, Kristina Masson, Jacob D. Jaffe, Whitney Silkworth, Nathan T. Ross, Christina A. Scherer, Claudia Scholl, Stefan Fröhling, Steven A. Carr, Andrew M. Stern, Stuart L. Schreiber, and Todd R. Golub. Stk33 kinase inhibitor brd-8899 has no effect on kras-dependent cancer cell viability. Proceedings of the National Academy of Sciences, 109:2860-2865, Feb 2012. URL: https://doi.org/10.1073/pnas.1120589109, doi:10.1073/pnas.1120589109. This article has 99 citations.

7. (spiridonov2005identificationandcharacterization pages 1-2): Nikolay A. Spiridonov, Lily Wong, Patricia M. Zerfas, Matthew F. Starost, Svetlana D. Pack, Cloud P. Paweletz, and Gibbes R. Johnson. Identification and characterization of sstk, a serine/threonine protein kinase essential for male fertility. Molecular and Cellular Biology, 25:4250-4261, May 2005. URL: https://doi.org/10.1128/mcb.25.10.4250-4261.2005, doi:10.1128/mcb.25.10.4250-4261.2005. This article has 155 citations and is from a domain leading peer-reviewed journal.

8. (spiridonov2005identificationandcharacterization pages 7-9): Nikolay A. Spiridonov, Lily Wong, Patricia M. Zerfas, Matthew F. Starost, Svetlana D. Pack, Cloud P. Paweletz, and Gibbes R. Johnson. Identification and characterization of sstk, a serine/threonine protein kinase essential for male fertility. Molecular and Cellular Biology, 25:4250-4261, May 2005. URL: https://doi.org/10.1128/mcb.25.10.4250-4261.2005, doi:10.1128/mcb.25.10.4250-4261.2005. This article has 155 citations and is from a domain leading peer-reviewed journal.

9. (spiridonov2005identificationandcharacterization pages 9-11): Nikolay A. Spiridonov, Lily Wong, Patricia M. Zerfas, Matthew F. Starost, Svetlana D. Pack, Cloud P. Paweletz, and Gibbes R. Johnson. Identification and characterization of sstk, a serine/threonine protein kinase essential for male fertility. Molecular and Cellular Biology, 25:4250-4261, May 2005. URL: https://doi.org/10.1128/mcb.25.10.4250-4261.2005, doi:10.1128/mcb.25.10.4250-4261.2005. This article has 155 citations and is from a domain leading peer-reviewed journal.

10. (sugiyama2019largescalediscoveryof pages 3-4): Naoyuki Sugiyama, Haruna Imamura, and Yasushi Ishihama. Large-scale discovery of substrates of the human kinome. Scientific Reports, Jul 2019. URL: https://doi.org/10.1038/s41598-019-46385-4, doi:10.1038/s41598-019-46385-4. This article has 119 citations and is from a poor quality or predatory journal.

11. (luo2012stk33kinaseinhibitor pages 2-3): Tuoping Luo, Kristina Masson, Jacob D. Jaffe, Whitney Silkworth, Nathan T. Ross, Christina A. Scherer, Claudia Scholl, Stefan Fröhling, Steven A. Carr, Andrew M. Stern, Stuart L. Schreiber, and Todd R. Golub. Stk33 kinase inhibitor brd-8899 has no effect on kras-dependent cancer cell viability. Proceedings of the National Academy of Sciences, 109:2860-2865, Feb 2012. URL: https://doi.org/10.1073/pnas.1120589109, doi:10.1073/pnas.1120589109. This article has 99 citations.

12. (spiridonov2005identificationandcharacterization pages 2-4): Nikolay A. Spiridonov, Lily Wong, Patricia M. Zerfas, Matthew F. Starost, Svetlana D. Pack, Cloud P. Paweletz, and Gibbes R. Johnson. Identification and characterization of sstk, a serine/threonine protein kinase essential for male fertility. Molecular and Cellular Biology, 25:4250-4261, May 2005. URL: https://doi.org/10.1128/mcb.25.10.4250-4261.2005, doi:10.1128/mcb.25.10.4250-4261.2005. This article has 155 citations and is from a domain leading peer-reviewed journal.

13. (spiridonov2005identificationandcharacterization pages 4-5): Nikolay A. Spiridonov, Lily Wong, Patricia M. Zerfas, Matthew F. Starost, Svetlana D. Pack, Cloud P. Paweletz, and Gibbes R. Johnson. Identification and characterization of sstk, a serine/threonine protein kinase essential for male fertility. Molecular and Cellular Biology, 25:4250-4261, May 2005. URL: https://doi.org/10.1128/mcb.25.10.4250-4261.2005, doi:10.1128/mcb.25.10.4250-4261.2005. This article has 155 citations and is from a domain leading peer-reviewed journal.

14. (bradley2019evolutionofprotein pages 2-3): David Bradley and Pedro Beltrao. Evolution of protein kinase substrate recognition at the active site. PLOS Biology, 17:e3000341, Jun 2019. URL: https://doi.org/10.1371/journal.pbio.3000341, doi:10.1371/journal.pbio.3000341. This article has 76 citations and is from a highest quality peer-reviewed journal.

15. (carter2010prioritizationofdriver pages 2-3): Hannah Carter, Josue Samayoa, Ralph H. Hruban, and Rachel Karchin. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (chasm). Cancer Biology &amp; Therapy, 10:582-587, Sep 2010. URL: https://doi.org/10.4161/cbt.10.6.12537, doi:10.4161/cbt.10.6.12537. This article has 109 citations.

16. (carter2010prioritizationofdriver pages 5-6): Hannah Carter, Josue Samayoa, Ralph H. Hruban, and Rachel Karchin. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (chasm). Cancer Biology &amp; Therapy, 10:582-587, Sep 2010. URL: https://doi.org/10.4161/cbt.10.6.12537, doi:10.4161/cbt.10.6.12537. This article has 109 citations.